How much do GLP-1 drugs actually cut alcohol craving and drinking?
The most direct evidence comes from a 2025 randomized controlled trial where 48 adults with alcohol use disorder received low-dose semaglutide or a placebo for 9 weeks [1]. Semaglutide reduced weekly alcohol craving by a statistically significant amount and cut the number of drinks per drinking day by about 41% compared to placebo. In a controlled lab setting, people on the drug also consumed less alcohol and had lower peak breath alcohol levels. A meta-analysis pooling three studies (431 patients) confirmed that GLP-1 agonists significantly improve alcohol cravings, with a large effect size [2]. Importantly, the same meta-analysis found a modest but significant reduction in episodes of heavy drinking and a meaningful drop in AUDIT scores (a standard measure of alcohol problems) by about 4.3 points [2].
However, the picture is not uniformly strong. The 9-week trial found that semaglutide did not reduce the average number of drinks per day or the number of drinking days overall—only the amount consumed on days when people did drink [1]. This suggests the drug may be more effective at limiting how much you drink when you start, rather than preventing drinking entirely. Also, an earlier trial with a different GLP-1 drug (exenatide) over 26 weeks found no significant reduction in drinking compared to placebo [3], so results may vary by specific drug and dose.
Beyond craving: real health gains in liver disease and survival
The most compelling evidence that GLP-1 effects on alcohol translate into major health improvements comes from a 2025 study of over 8,000 U.S. veterans with harmful alcohol use [4]. Those who started a GLP-1 drug had a 30% lower risk of developing serious liver complications (like liver failure or liver cancer) and a 57% lower risk of death from any cause over the follow-up period. Importantly, the study also found that GLP-1 users were 25% less likely to have a positive alcohol screening test during follow-up, directly linking the drug to reduced harmful drinking [4]. The higher the dose of semaglutide, the greater the protection: each 1 mg/week increase was associated with a 50% lower risk of liver complications and a 67% lower risk of death [4].
This is a huge deal because alcohol-related liver disease is a leading cause of death, and current treatments have limited impact on liver outcomes. The study design (a "target trial emulation") is observational, not a randomized trial, so it can't prove cause and effect, but the size and consistency of the effect are striking. Animal research backs this up: in alcohol-preferring monkeys, semaglutide significantly reduced voluntary alcohol intake without causing nausea or reducing water intake [5].
How do GLP-1 drugs reduce alcohol cravings?
GLP-1 drugs work through multiple pathways that go beyond simple appetite suppression. First, they act directly on the brain's reward system—the same dopamine pathways that make alcohol feel rewarding [3]. By dampening this reward signal, the drugs reduce the "wanting" of alcohol. Second, they slow down stomach emptying, which means alcohol is absorbed more slowly into the bloodstream, leading to lower peak blood alcohol levels and less intense intoxication [3]. This can weaken the link between drinking and feeling good, reducing the drive to drink more.
A clever 2025 lab study with 40 heavy drinkers showed that even a temporary increase in the body's own GLP-1 (triggered by a dietary supplement) reduced their attentional bias toward alcohol—meaning they were less automatically drawn to alcohol-related cues [6]. This suggests that GLP-1's effect on craving is at least partly about changing how your brain responds to the sight or thought of alcohol, not just how you feel after drinking. The same study found no effect on subjective feelings of intoxication, so the drug seems to target the motivational "pull" of alcohol rather than the experience of being drunk [6].
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2024 to 2026, 6 from 2024 or later, 2 in Q1 journals, collectively cited 161 times — selected as the most relevant from 6 studies that passed quality screening, drawn from 67 papers retrieved from a database of over 500 million.
Sources used in this answer
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
In a 9-week randomized controlled trial with 48 adults with alcohol use disorder, low-dose semaglutide significantly reduced alcohol craving, drinks per drinking day (by about 41%), and alcohol consumed in a lab setting, but did not reduce overall drinking days or average drinks per day [1].
SUN-576 Glucagon-like Peptide-1 (GLP-1) Receptor Agonists For Alcohol Use Disorder: a Systematic Review and Meta-analysis
A meta-analysis of three studies (431 patients) found that GLP-1 agonists significantly improved alcohol cravings (large effect size), reduced heavy drinking episodes, and lowered AUDIT scores by about 4.3 points [2].
Glucagon‐like peptide‐1 receptor agonists in alcohol use disorder: Multi‐system effects, early clinical promise and uncertain long‐term use
A review article notes that while GLP-1 drugs show early promise for alcohol use disorder via central reward and peripheral metabolic effects, long-term efficacy, optimal dosing, and effects after discontinuation remain uncertain; an earlier exenatide trial found no significant reduction in drinking [3].
Association of GLP-1 Receptor Agonists with Liver-Related Outcomes and All-Cause Mortality in Patients with Harmful Alcohol Use: A Target Trial Emulation Study.
In a target trial emulation study of 8,040 veterans with harmful alcohol use, GLP-1 drug initiation was associated with a 30% lower risk of liver complications, 57% lower all-cause mortality, and 25% lower odds of a positive alcohol screen during follow-up [4].
Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys
In alcohol-preferring male vervet monkeys, semaglutide significantly reduced voluntary alcohol intake compared to vehicle, with no signs of nausea or changes in water intake [5].
Associations between acute changes in GLP-1 and alcohol responses, craving, and attentional bias: A randomized, placebo-controlled laboratory study
In a randomized lab study with 40 heavy drinkers, a dietary supplement that raised endogenous GLP-1 levels significantly reduced attentional bias toward alcohol cues, suggesting GLP-1 can lower implicit motivation for alcohol [6].